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Abstract
Purpose of review: Chemical properties of the widely-used older generation
antiepileptic drugs (AEDs) suggest that they might be responsible for a number
of medical co-morbidities.

Recent findings: AEDs which induce the cytochrome P450 system adversely
affect bone, lipid, and gonadal steroid metabolism. Specifically, phenytoin (PHT)
causes loss of bone mass in women, and both PHT and carbamazepine (CBZ)
produce increases in serum lipids and C-reactive protein, as well as decreases
in bioactive testosterone in men. Patients treated with inducing AEDs are at
increased risk of fracture. Some contradictory data raise the question of whether
bone mass is truly related to enzyme induction, and analogously, of whether
reductions in testosterone truly account for male sexual dysfunction. Data
showing elevations of surrogate cardiovascular and cerebrovascular risk
endpoints with epilepsy patients, mostly inducing AED-treated, are consistent
and concerning, however. Another older AED, valproate, is associated with the
occurrence of polycystic ovary syndrome when used in young adulthood or
adolescence.

Summary: Older generation AEDs are associated with a panoply of metabolic
abnormalities. While more research is needed to see whether individual drugs
are directly tied to specific clinical outcomes (e.g. risk of infarction), extant data
are sufficiently concerning to suggest that these drugs may produce significant
adverse health consequences. Newer generation AEDs may be preferable.

Keywords: antiepileptic drugs, lipids, bone, polycystic ovary syndrome, enzyme
induction

Introduction

It is uncommon for a patient to ask of her antihypertensive, antiplatelet
agent, or proton pump inhibitor, “What will this medication do to me over the long
term?” Yet patients with epilepsy ask this question routinely regarding their
antiepileptic therapy, and it seems they have good reason: among the many
classes of drugs prescribed for chronic use, antiepileptic drugs (AEDs) appear to
have a unique proclivity for affecting metabolism in unanticipated ways. Much of
this stems from the property, shared by many AEDs, of altering the effects of
enzymes of the cytochrome P450 (CYP450) system. Research over the last two
decades has revealed that the CYP450 system plays a prominent role in many
metabolic pathways, not just drug metabolism as had initially been believed (and
as many physicians still believe). The involvement of the CYP450 system in the
metabolism of hormones, vitamins, cholesterol, and other substances forms the
scientific underpinning for the empiric observation that many AEDs — especially
those which induce the CYP450 system — produce alterations in these
pathways, accompanied by additional effects of potential clinical significance.
An understanding of these effects is critical to the optimal care of patients
who are treated with these agents, which include not only those with seizures,
but also those with essential tremor, migraine, neuralgic pain syndromes, and
psychiatric conditions. All of these disorders require long-term — often lifelong
— treatment, making the potential slow accretion of metabolic effects a genuine
risk. This review is an attempt to provide a capsule summary of the current state
of knowledge regarding the metabolic effects of AEDs, highlighting the most
recent evidence for clinically-relevant effects and concluding with
recommedations for patient care and future research.

Bone and Vitamin D metabolism

Observations regarding the effects of AEDs on bone mass first surfaced in

the medical literature four decades ago. The prevailing hypothesis underlying
this concern, and the evidence for and against it, were nicely reviewed in a
recent manuscript (1). Briefly, the notion is that CYP450-inducing AEDs
upregulate the enzymes responsible for the metabolism of vitamin D, leading it
to be processed into inactive metabolites. Compensation for this necessitates
increased conversation of the major storage form, 5-hydroxyvitamin D (25-OHD),
to the active forms. Upregulating this reaction requires increased levels of
parathyroid hormone (PTH) as a necessary cofactor. A side consequence of this
increase in PTH is an increase in bone turnover, and this “churn” through bone
eventually leads to significant loss of bone mass.
A substantial body of evidence indicates that the inducing AEDs are
associated with reduced levels of 25-OHD, with the largest amount of evidence
impugning carbamazepine (CBZ) (2-9)(10, 11) (Table 1). Other studies suggest
increases in bone turnover markers in patients treated with the inducers CBZ or
phenytoin (PHT), whereas bone turnover appears normal in patients taking the
non-inducing drug lamotrigine (LTG) (6, 10). A well-done community-based
investigation demonstrated rather convincingly that PHT is associated with
accelerated bone loss in elderly women (12), and there is also evidence from
case-control studies of increased fracture risk in patients taking inducing AEDs
(13, 14). Yet not all of the available evidence is consistent with this hypothesis.
Studies of patients taking CBZ have yielded mixed results regarding its effects
on bone density (4, 15, 16). In addition, the enzyme-inhibiting drug valproate
(VPA) has been implicated as a potential cause of reduced bone density(15, 16)
and fracture risk (13, 14).
Into this breach have stepped a number of recent studies, which
unfortunately serve to muddy the waters even further. Pack and colleagues (11)
followed women on AED monotherapy with PHT, CBZ, LTG or VPA for a year.
They found significant loss of bone at the femoral neck in PHT-treated patients;
they also found that reductions in 25-OHD were associated with increases in
bone turnover markers, all of which is consistent with the aforementioned
prevailing hypothesis. Yet CBZ-treated patients, in whom one would expect
similar results, showed no such changes, nor did those on VPA or LTG. This

study suggests that the effects of individual enzyme-inducing AEDs on bone
may differ.
Another noteworthy study in this arena was a large, community-based study
of elderly men in whom bone density was measured twice, an average of 4.6
years apart (17). After adjustment for a large number of potential confounders,
those taking inducing AEDs had a rate of bone loss no different from controls,
whereas those taking non-inducing AEDs had an accelerated rate of bone loss;
in fact, this was larger in patients who were being treated at both time points
than in patients who were being treated only at one time point, consistent with a
dose-response relationship. This surprising result flies in the face of all previous
expectations, and while the study appears quite methodologically sound, this
author has reservations about its conclusions. One possible source of error
concerns the study population: of the patients taking non-inducing AEDs, the
vast majority (over 80%) were being treated with gabapentin, a drug which is
ovewhelmingly prescribed for pain rather than epilepsy in current practice. One
wonders if the disease states for which these patients were taking gabapentin
might have influenced their bone health relative to controls. Even if one sets
aside this caveat, the results should be considered applicable to gabapentin
specifically rather than to all non-inducing AEDs.
Another case control study of fracture incidence was recently published,
demonstrating that hip fractures were significantly associated with a history of
AED use, and that all of this risk accrued with the use of inducing rather than
non-inducing AEDs (18). This reconfirms the results of other case-control studies
(13, 14).
Data on specific newer AEDs is largely lacking, aside from previouslymentioned studies which included LTG (10, 11) and one study suggesting that
patients treated with oxcarbazepine (OXC) had lower 25-OHD levels and
increased bone turnover (6). The latter was replicated in another recent
publication, which found that 18 months of OXC treatment in children resulted in
higher bone turnover and lower 25-OHD, but no significant change in bone
density(19).
Finally, to round out the confusion, one study found that bone density was

reduced in patients treated with either inducing or non-inducing AEDs but was
worse in the former(20). Duration of AED therapy, with any kind of AED, was
also associated with greater bone loss. This study is limited by its crosssectional design.

Lipids and other vascular risk markers

A number of serologic markers which are relevant to cardiovascular risk
have been found to be affected by the CYP450-inducing AEDs. These include
cholesterol and specific atherogenic lipid fractions (21-23), lipoprotein(a) (23), and
homocysteine (24). These alterations suggest that enzyme-inducing AEDs might
produce elevations in cardiovascular risk, a notion reinforced by the
epidemiologic data, most of which demonstrates that patients with epilepsy
suffer from greater vascular mortality and morbidity than the general population
(25-27)(28, 29) (Table 2). In fact, carotid intima-media thickness, which has proven
itself a robust surrogate marker for both cardiovascular and cerebrovascular
disease, has been shown to be elevated among epilepsy patients, particularly in
those taking inducing AEDs (30, 31), supporting the notion that atherosclerosis in
increased in this population. Most of these studies are cross-sectional in nature,
which limits their ability to inform causative inferences.
One recent investigation directly examined the effects of switching from
inducing to non-inducing AEDs on vascular risk markers (32). In this study, 34
patients on CBZ or PHT in monotherapy were crossed over to monotherapy with
either LTG or levetiracetam (LEV). Serologic studies, including lipid profiles,
lipoprotein(a) {Lp(a)}, homocysteine (HCY) and C-reactive protein (CRP) were
performed before the switch and then once again 6 weeks after discontinuation
of the old drug. Sixteen normal subjects who were not treated with an AED
underwent the same serologic studies on two occasions to serve as a control
group. After drug switch, the epilepsy patients showed a mean decline of 25 mg/
dL in total cholesterol, mostly in its atherogenic fractions, as well as a decline of
nearly a third in CRP. In addition, patients withdrawn from CBZ experienced a

sharp reduction in Lp(a), while those withdrawn from PHT had subsequent
reductions in HCY. Whether patients were switched to LTG or LEV had no
bearing on the outcome measures, suggesting that CYP450 de-induction was
responsible for the observed changes, and that the vascular risk markers in
question were likely increased by CBZ and PHT to begin with.
Further evidence for increased vascular risk in this population was provided
by Tan et al(33), who obtained a series of serologic studies along with carotid
intimal-medial thickness measurements in 195 patients with epilepsy and in
controls. They found that epilepsy patients had higher levels of total cholesterol,
CRP, and HCY, as well as increased carotid intimal-medial thickness,
corroborating a likely increased risk of cardiac and cerebral ischemic disease.
Multivariate analysis revealed that duration of AED therapy was significantly
correlated with carotid thickness. This study is noteworthy because of its large
size and its use of a strong and well-validated surrogate measure of vascular
disease. An important weakness is that the results were not presented in a way
that allows for the specific elucidation of the effects of enzyme inducers, as it
appears that a group of patients taking inducers alone were compared with a
polytherapy group, many of whom were likely on inducers as well.
Consistent with the two aforementioned studies, Tomoum et al(34) studied
22 children with epilepsy and found that total cholesterol, various lipid fractions,
and apolipoprotein AI were elevated in CBZ-treated patients and reduced in VPAtreated patients relative to controls, reinforcing the notion that CYP450 activity is
causative of these changes. Carotid intimal-medial thickness was measured as
well, but the sample was small and this was not analyzed appropriately.

Reproductive hormones
Both enzyme inducers and VPA have been implicated in effects on
reproductive hormones. Controversy has been present since the first
demonstration that VPA is frequently associated with a constellation of
symptoms resembling polycystic ovary syndrome (PCOS)(35). Verification of
this cross-sectional study would be ideally done by prospectively examining

either the results of drug switch or the effects of randomized drug assignment. A
study of the former type was published not long after the original report,
documenting that patients with PCOS who were taking VPA had resolution of all
symptoms following switch to LTG, conclusively demonstrating that the drug
was causative of the symptoms in these patients(36). Now a study of the latter
type has appeared, shedding further light on this assocation(37). A multinational
team of investigators randomized a group of epilepsy patients, both newlydiagnosed and refractory, to treatment with either VPA or LTG for a mean of
almost a year. Both clinical and endocrinologic evidence of PCOS were
significantly more frequent in the patients receiving VPA, but only in women age
25 and younger. This may help to reconcile some of the conflicting evidence and
opinion surrounding this issue, and also may provide some support for the use of
VPA in women older than 25, at least when pregnancy is not planned(38).
Reproductive hormone function among men with epilepsy has also been a
subject of active investigation, with one study demonstrating that men taking the
enzyme-inducing drugs CBZ or PHT had significantly lower testosterone levels
and lower sexual function scores than men with epilepsy who were taking LTG or
who were untreated (39). In this cohort, testosterone levels and sexual function
were significantly correlated, suggesting that CBZ and PHT induce testosterone
metabolism, leading to clinically-relevant sexual impairment. While this story
appears scientifically sound and sensible, conflicting evidence has recently been
published (40). The latter investigators performed a similar study of both men
with epilepsy and controls, but with the addition of validated measures of
depression and anxiety. They confirmed the previous finding that men taking
inducing AEDs had lower testosterone levels, but found that virtually all were still
above the threshold needed for normal sexual function, and that testosterone
levels did not correlate with sexual function scores. These scores were clearly
lower in men with epilepsy, but were correlated with depression and anxiety
rather than the hormonal measures. The reasons for the discrepancies between
this study and previous studies remains unclear, and more work will clearly need
to be done to further elucidate these findings.

Conclusions
Recent studies have added to the considerable evidence that AEDs,
particularly the older-generation agents, may have diffuse and profound effects
upon a variety of metabolic pathways. The several discussed here do not
include others which are complex enough to engender full-fledged discussions of
their own (e.g. drug interactions, teratogenicity). A common thread runs through
much of this data: it is clear that enzyme-inducing AEDs produce substantial
alterations of a host of serologic parameters, but demonstration of the clinical
end effects of those changes remain to be elucidated. Thus, patients with
epilepsy are at increased risk for fractures, and PHT and CBZ lower vitamin D
levels, but only the former drug has been clearly shown to affect bone density,
and it is not clear that reduction in vitamin D is responsible. In a similar vein,
patients with epilepsy have significantly higher rates of cardiovascular and
cerebrovascular disease, and there is mounting evidence that PHT and CBZ are
clearly responsible for elevations of several strong and well-validated vascular
surrogate markers, but epidemiologic data to compare the rate of vascular
events attributable to specific drugs is lacking.
Another common thread is that the effects of individual drugs may differ;
thus, while CBZ and PHT appear to have similar effects on cholesterol,
testosterone, and 25-OHD levels, their effects on Lp(a) and bone density are
different. More research is clearly needed to explore the mechanisms underlying
these effects.
In addition, further research is needed to fill in these gaps regarding the
effects of specific drugs on particular health outcomes (e.g. myocardial
infarction, fracture); such studies will be large and challenging epidemiologically
and will require independent (not corporate) funding. Equally important will be
determination of the other side of the clinical equation: the relative efficacy of
the various drugs for seizure prevention. This is all the more relevant given the
availability of a whole generation of AEDs, almost all chemically distinct, that
likely avoid adverse metabolic effects. Funding for such research should
hopefully be readily available in light of the U.S. governmentʼs newfound interest
in comparative treatment efficacy. Study of this kind is desperately needed in

the field of epilepsy, where we lack any data to answer one of our most basic
practice questions: if a patient is seizure-free on a drug, what is the likelihood
that she will remain seizure-free on a different drug?
The latter point is germane to the concluding opinion of this review. The
author is already on record with his views regarding the practical import of the
manifold metabolic effects elucidated herein (32, 41). At the very least, all
patients taking an older-generation AED, whether for epilepsy or any other
indication, should be aggressively screened for the appropriate clinical
consequences; this would include cardiac risk serology for those taking
inducers, signs and symptoms of PCOS for women taking VPA, and bone
density testing (as well as vigilance against potential drug interactions) in both
groups. If metabolic complications are found, they may be treated, but switching
to another AED may well be better medical practice, as it might reduce costs,
complications, and co-morbidities. In any case, the specter of these potential
metabolic complications make it difficult to recommend the use of older AEDs
as first-line therapy at the present time, pending better data regarding
comparative efficacy.
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Table 1. Studies comparing 25-hydroxyvitamin D levels in carbamazepine-treated
patients and in subjects not taking an enzyme-inducing drug

Study

CBZ pts

Control pts

% Δ from ctrl

Pack 2008(11)

23.4

25.2*

-7%

Kim 2007(4)

23.0

33.8*

-32%

Mintzer 2006(6)

20.4

27.5

-26%

Pack 2005(10)

21.0

30.0*

-33%

Verrotti 2002(8)

26.2

27.0

-3%

Verrotti 2000(9)

38.7

39.0

-1%

Lamberg-Allardt
1990(5)

22.8

27.5

-17%

Gough 1986(2)

22.9

39.2

-42%

Hoikka 1984(3)

11.1

17.6

-37%

Tjellesen 1983(7)

22.9

26.2

-13%

Controls were untreated with any antiepileptic drugs except for the values marked with an asterisk*, which
represent lamotrigine-treated control subjects. CBZ = carbamazepine. % ∆ from ctrl = percentage
difference in 25-hydroxyvitamin D levels in the CBZ-treated group relative to the control group. All values
in ng/mL.

TABLE 2. Vascular mortality and morbidity in patients with epilepsy, general population
studies

Mortality Study

Study size (followup)

Standardized
mortality ratio

Ding et al (25)

5,114 person-years

Myocardial infarction:

Nilsson et al(26)

53,250 person-years

Ischemic heart
disease: 2.5*
Cerebrovascular
disease: 5.3*
Ischemic heart
disease: 1.2
Cerebrovascular
disease: 3.7*
Ischemic heart
disease: 1.2
IHD, patients age
25 - 44: 5.7*
IHD, patients age
45 - 64: 2.5*

Cockerell et al(27)

Annegers et al(28)

10.7*

7,528 person-years

“Approached 10,000
person-years”

Morbidity study

Total epilepsy
population

Morbidity
(prevalence) ratio

Gaitatzis et al (29)

N=5843

Ischemic heart
disease: 1.34*
Ischemic heart
disease (age < 65):

1.63*

Annegers et al(28)

N=725

Cerebrovascular
disease: 6.96*
Cerebrovasc. Disease
(age <65): 14.19*
Ischemic heart
disease: 1.63*
IHD, idiopathic
epilepsy only: 1.49*

95% confidence
interval
5.6 - 95.3
2.3 - 2.7
4.9 – 5.8
0.7 - 1.9
2.4 – 5.4
0.9 – 1.5
1.8 – 13.3
1.4 – 4.1

95% confidence
interval
1.19 – 1.5
1.34 – 1 .98
6.38 – 7 .6
12.04 – 16 .73

1.2 – 2.15
1.00 – 2 .15

Data marked with an asterisk* are statistically significant (i.e. the lower limit of the 95% confidence
interval is ≥ 1). IHD: ischemic heart disease.
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